# LIBRETTO-432 (NCT04819100)

> A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04819100
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Selpercatinib; Placebo
- Enrollment: 152
- Primary outcome: Event-Free Survival (EFS)

## Commentary we found

- X threads: 79
- YouTube: 22
- Podcasts: 18
- X videos: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=libretto-432-nct04819100

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04819100", "email": "<work email>"}; the inbox owner confirms by the emailed link.